Viper Energy, Inc. filed a Form 8-K on September 16, 2026, disclosing that its Board of Directors appointed John Grotzinger as a new director, effective September 15, 2026, expanding the board to nine members.
Oaktree Specialty Lending Corporation filed a Form 8-K on September 16, 2026, disclosing the closing of a $300.0 million offering of 7.000% Notes due 2031 and the execution of a Ninth Supplemental Indenture with Deutsche Bank Trust Company Americas as trustee.
Gossamer Bio, Inc. filed a Form 8-K on September 16, 2026, disclosing the appointment of Gregory A. Ciongoli as a Class III director and member of the Audit Committee, effective September 16, 2026.
nVent Electric plc filed a Form 8-K on September 16, 2026, disclosing that its subsidiary Hoffman Schroff Holdings, Inc. entered into an Underwriting Agreement on September 15, 2026, to sell $800.0 million aggregate principal amount of 6.150% Senior Notes due 2036 in a public …
Ally Financial Inc. filed a Form 8-K on September 16, 2026, disclosing the issuance of $750,000,000 aggregate principal amount of 5.525% Fixed-to-Floating Rate Senior Notes due 2030 under a previously effective shelf registration statement.
Horizon Bancorp, Inc. filed a Form 8-K on September 16, 2026, disclosing that its Board of Directors approved a cash dividend of $0.16 per share on September 15, 2026.
AECOM filed a current report on September 16, 2026, disclosing that Chief Legal Officer David Gan notified the company of his intention to retire and that General Counsel Manav Kumar will succeed him effective October 2, 2026.
Martin Marietta Materials, Inc. filed an 8-K with the SEC on September 16, 2026, disclosing that it entered into the Eighteenth Amendment to its Credit and Security Agreement on September 15, 2026, extending the maturity of its trade receivables securitization facility to September 15, …
EagleRock Land, LLC filed a Form 8-K on September 16, 2026, reporting that its board of directors approved long-term incentive awards of Performance Share Units and Restricted Share Units to its Chief Executive Officer and Chief Financial Officer on September 10, 2026.
Avalyn Pharma Inc. filed an 8-K on September 16, 2026, disclosing that its Board of Directors appointed Robert Meyer, M.D. as a Class II director, effective September 15, 2026.